全文获取类型
收费全文 | 52182篇 |
免费 | 3695篇 |
国内免费 | 178篇 |
专业分类
耳鼻咽喉 | 601篇 |
儿科学 | 1052篇 |
妇产科学 | 793篇 |
基础医学 | 6667篇 |
口腔科学 | 693篇 |
临床医学 | 4848篇 |
内科学 | 12476篇 |
皮肤病学 | 533篇 |
神经病学 | 5157篇 |
特种医学 | 2090篇 |
外科学 | 8440篇 |
综合类 | 578篇 |
一般理论 | 65篇 |
预防医学 | 3588篇 |
眼科学 | 921篇 |
药学 | 3181篇 |
中国医学 | 50篇 |
肿瘤学 | 4322篇 |
出版年
2023年 | 255篇 |
2022年 | 226篇 |
2021年 | 1266篇 |
2020年 | 900篇 |
2019年 | 1294篇 |
2018年 | 1642篇 |
2017年 | 1122篇 |
2016年 | 1206篇 |
2015年 | 1441篇 |
2014年 | 2166篇 |
2013年 | 2514篇 |
2012年 | 4333篇 |
2011年 | 4298篇 |
2010年 | 2408篇 |
2009年 | 2153篇 |
2008年 | 3767篇 |
2007年 | 3870篇 |
2006年 | 3742篇 |
2005年 | 3685篇 |
2004年 | 3290篇 |
2003年 | 3026篇 |
2002年 | 2736篇 |
2001年 | 314篇 |
2000年 | 204篇 |
1999年 | 302篇 |
1998年 | 416篇 |
1997年 | 364篇 |
1996年 | 277篇 |
1995年 | 317篇 |
1994年 | 248篇 |
1993年 | 231篇 |
1992年 | 145篇 |
1991年 | 131篇 |
1990年 | 116篇 |
1989年 | 101篇 |
1988年 | 89篇 |
1987年 | 78篇 |
1986年 | 83篇 |
1985年 | 102篇 |
1984年 | 126篇 |
1983年 | 106篇 |
1982年 | 138篇 |
1981年 | 109篇 |
1980年 | 94篇 |
1979年 | 45篇 |
1978年 | 58篇 |
1977年 | 55篇 |
1976年 | 51篇 |
1975年 | 37篇 |
1974年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
3.
4.
Nicolas Zhou Matthew Bott Bernard J. Park Eric Vallières Candice L. Wilshire Kazuhiro Yasufuku Jonathan D. Spicer David R. Jones Boris Sepesi 《The Journal of thoracic and cardiovascular surgery》2021,161(3):760-771.e2
BackgroundAdjuvant chemotherapy, postoperative radiation (PORT), and prophylactic cranial irradiation (PCI) have been individually examined in limited-stage small cell lung cancer (SCLC). There is a paucity of data on the effectiveness of each adjuvant treatment modality when used in combination after surgical resection of SCLC.MethodsData were collected from 5 cancer centers on all patients with limited-stage SCLC who underwent surgical resection between 1986 and 2019. Univariate and multivariable models were conducted to identify predictors of long-term outcomes, focusing on freedom from recurrence and survival benefit of adjuvant chemotherapy, PORT, and PCI.ResultsA total of 164 patients were analyzed. Multivariable Cox regression analysis did not identify any adjuvant therapies to significantly influence recurrence in this cohort. Specifically, PORT was not associated with a significant influence on locoregional recurrence and PCI was not significantly associated with intracranial outcomes. Adjuvant chemotherapy improved survival in all stage I through III disease (hazard ratio, 0.49; 95% confidence interval, 0.29-0.81; P = .005) and even in pathologically node negative patients (hazard ratio, 0.49; 95% confidence interval, 0.27-0.91; P = .024). Although PCI was found to improve survival in univariate analysis, it was not significant in a multivariable model. PORT was not found to affect survival on either univariate or multivariable analysis.ConclusionsThis is among the largest multi-institutional studies on surgically resected limited-stage SCLC. Our results highlight survival benefit of adjuvant chemotherapy, but did not identify a statistically significant influence from mediastinal PORT or PCI in our cohort. Larger prospective studies are needed to determine the benefit of PORT or PCI in a surgically resected limited-stage SCLC population. 相似文献
5.
6.
Matrine,oxymatrine, and compound Kushen injection from the roots of Sophora flavescens: an overview of their anticancer activities 下载免费PDF全文
In the present review, we updated current information on the chemistry, contents, and anticancer properties of matrine (MT), oxymatrine (OMT), and compound Kushen injection (CKI). The anticancer properties were focused on lung, breast, and liver cancer cells because they are most susceptible. Sources of information were from Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, Directory of Open Access Journals (DOAJ), and China National Knowledge Infrastructure (CNKI). Reference was also made on botanical websites, such as Flora of China and World Flora Online. MT and OMT are dominant quinolizidine alkaloids from the roots of Sophora flavescens (Kushen) of the family Fabaceae. Against lung, breast, and liver cancer cells, MT and OMT inhibit cell proliferation; induce cell cycle arrest, apoptosis, and autophagy; restrict angiogenesis; and inhibit cell metastasis, invasion, and migration. The processes involve various molecular targets and signaling pathways. CKI is a traditional Chinese medicine (TCM) composed of root extracts of S. flavescens and Smilax glabra (Baituling) of the family Smilacaceae. With MT and OMT as major components, CKI has been approved for the treatment of cancer in China more than 20 years ago. In recent years, systematic reviews and meta-analysis have been undertaken to evaluate the anticancer effects of CKI. When CKI is used alone and in combination with chemotherapy of western medicine, there is much to be learned concerning their interactions besides their individual and integrated efficacy. Some perspectives of MT, OMT, and CKI are discussed, and their suggestions for future research are provided. 相似文献
7.
8.
9.
10.